Cancer has traditionally been classified by microscopic examination of tissue subtypes (such as lung, bowel, and skin) and the cell types involved. Increasingly, tumours are now also categorized according to molecular criteria, or changes in DNA.
For example, some cancers will respond differently to treatments with certain classes of drugs, depending on the presence or absence of certain mutations (or molecular variants). Testing and treating tumours in this way is also known as precision or personalised medicine.
Some families may have an increased risk of developing certain types of cancer through the inheritance of variants (mutations) in certain genes. Testing for these variants can determine whether you might be at increased risk of developing cancer and suggest an appropriate prevention or surveillance strategy.
Genomic Diagnostics is NATA accredited for the full range of tumour genetic testing methods, including both inherited cancer susceptibility testing (inherited, or germline testing), and tumour stratification of solid and haematological malignancies for therapeutic, diagnostic or prognostic purposes (somatic testing).